TY - JOUR
T1 - Independent risk factors for death in patients admitted for asthma exacerbation in Taiwan
AU - Chang, Yuh Lih
AU - Ko, Hsin Kuo
AU - Lu, Meng Shui
AU - Chou, Chia Lin
AU - Su, Kang Cheng
AU - Hsu, Chia Chen
AU - Chou, Kun Ta
AU - Chen, Tzeng Ji
AU - Perng, Diahn Warng
AU - Chou, Yueh Ching
N1 - Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - The independent risk factors for death in patients admitted for asthma exacerbation have not been thoroughly investigated. This study aimed to investigate these independent risk factors and the relationship between mortality and the prescription patterns of anti-asthmatic medications in patients admitted for asthma exacerbation. Using a nested case–control design, we identified 267 cases (death after asthma admission) and 1035 controls (survival after asthma admission) from the Taiwan National Health Insurance Research Database (NHIRD) from 2001 to 2010. Conditional logistic regressions were used to estimate the odds ratios (ORs) with 95% confidence intervals (CIs). We identified the independent risk factors for death as the comorbidities of pneumonia (aOR 3.82, 95% CI 2.41–6.05), genitourinary disease (aOR 1.75, 95% CI 1.17–2.62), septicemia (aOR 4.26, 95% CI 2.61–6.94), diabetes mellitus (aOR 2.10, 95% CI 1.30–3.38), arrhythmia (aOR 2.00, 95% CI 1.14–3.50), and a history of asthmatic hospitalization (aOR 4.48, 95% CI 2.77–7.25). Moreover, the use of short-acting β2-agonist (SABA) and the dosage of oral corticosteroids (OCSs) >70 mg prednisolone during previous hospitalization (all p < 0.05) and the dosage of OCSs ≥110 mg prednisolone/month (aOR 2.21, 95% CI 1.08–4.50) during outpatient treatment independently increased the risk of death. The inhaled corticosteroids (ICSs) ≥4 canisters/year (aOR 0.39, 95% CI 0.19–0.78) independently reduced the risk of death. Specific comorbidities, asthma severity, and prescription patterns of SABA, OCSs, and ICSs were independently associated with mortality in patients admitted for asthma exacerbation. These results can be utilized to help physicians identify asthmatic patients who are at a higher mortality risk and to refine the management of the condition.
AB - The independent risk factors for death in patients admitted for asthma exacerbation have not been thoroughly investigated. This study aimed to investigate these independent risk factors and the relationship between mortality and the prescription patterns of anti-asthmatic medications in patients admitted for asthma exacerbation. Using a nested case–control design, we identified 267 cases (death after asthma admission) and 1035 controls (survival after asthma admission) from the Taiwan National Health Insurance Research Database (NHIRD) from 2001 to 2010. Conditional logistic regressions were used to estimate the odds ratios (ORs) with 95% confidence intervals (CIs). We identified the independent risk factors for death as the comorbidities of pneumonia (aOR 3.82, 95% CI 2.41–6.05), genitourinary disease (aOR 1.75, 95% CI 1.17–2.62), septicemia (aOR 4.26, 95% CI 2.61–6.94), diabetes mellitus (aOR 2.10, 95% CI 1.30–3.38), arrhythmia (aOR 2.00, 95% CI 1.14–3.50), and a history of asthmatic hospitalization (aOR 4.48, 95% CI 2.77–7.25). Moreover, the use of short-acting β2-agonist (SABA) and the dosage of oral corticosteroids (OCSs) >70 mg prednisolone during previous hospitalization (all p < 0.05) and the dosage of OCSs ≥110 mg prednisolone/month (aOR 2.21, 95% CI 1.08–4.50) during outpatient treatment independently increased the risk of death. The inhaled corticosteroids (ICSs) ≥4 canisters/year (aOR 0.39, 95% CI 0.19–0.78) independently reduced the risk of death. Specific comorbidities, asthma severity, and prescription patterns of SABA, OCSs, and ICSs were independently associated with mortality in patients admitted for asthma exacerbation. These results can be utilized to help physicians identify asthmatic patients who are at a higher mortality risk and to refine the management of the condition.
UR - http://www.scopus.com/inward/record.url?scp=85082089898&partnerID=8YFLogxK
U2 - 10.1038/s41533-020-0164-4
DO - 10.1038/s41533-020-0164-4
M3 - Article
C2 - 32193384
AN - SCOPUS:85082089898
SN - 2055-1010
VL - 30
JO - npj Primary Care Respiratory Medicine
JF - npj Primary Care Respiratory Medicine
IS - 1
M1 - 7
ER -